N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
University of California, San Francisco
University of Iowa
University of Oklahoma
Mayo Clinic
Gruppo Oncologico Italiano di Ricerca Clinica
University Hospitals Bristol and Weston NHS Foundation Trust
Peking University Cancer Hospital & Institute
M.D. Anderson Cancer Center
University of Washington
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Thomas Jefferson University
Istituto Clinico Humanitas
Jonsson Comprehensive Cancer Center
University of Oklahoma
University of California, Davis
University of Texas Southwestern Medical Center
Brigham and Women's Hospital
University of Utah
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Sun Yat-sen University
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Mayo Clinic
University of Iowa
M.D. Anderson Cancer Center
Tampere University Hospital
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Fox Chase Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
First Affiliated Hospital of Wenzhou Medical University
Centre Francois Baclesse
University of Florida
Fudan University
Fudan University
Thomas Jefferson University
Nagoya University